Alnylam and The Medicines Co run PCSK9 race together through $205m alliance
This article was originally published in Scrip
Executive Summary
With an exclusive global alliance worth up to $205 million plus double-digit royalties to develop and commercialize Alnylam Pharmaceuticals' ALN-PCS, the RNAi specialist and The Medicines Company are in a crowded field of companies with hypercholesterolemia therapies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates low-density lipoprotein (LDL).
You may also be interested in...
The Medicines Co. CEO Timney On Selling Inclisiran And Why Big Pharma Is Still Interested In CV Disease
Mark Timney took over the helm at The Medicines Company in December with a singular focus: wrapping up the Phase III program for inclisiran and finding a buyer for the cholesterol-lowering drug.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.